Clinical Trial Update: An Extension Study for Patients Previously Enrolled in Studies With Pelabresib [Phase 3]

View source ↗

Summary

An extension study for patients who previously enrolled in pelabresib studies, currently recruiting in Phase 3 under Novartis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancies
• Solid Tumors

Drugs mentioned

• Pelabresib (pelabresib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Hematologic Malignancy, Solid Tumor | Phase 3 | Status: RECRUITING